ARWR Relative Valuation
ARWR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ARWR is overvalued; if below, it's undervalued.
Historical Valuation
Arrowhead Pharmaceuticals Inc (ARWR) is now in the Undervalued zone, suggesting that its current forward PS ratio of 8.32 is considered Undervalued compared with the five-year average of -29.72. The fair price of Arrowhead Pharmaceuticals Inc (ARWR) is between 26.70 to 70.24 according to relative valuation methord. Compared to the current price of 16.76 USD , Arrowhead Pharmaceuticals Inc is Undervalued By 37.24%.
Relative Value
Fair Zone
26.70-70.24
Current Price：16.76
37.24%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
3.70
P/B
Median3y
11.88
Median5y
12.83
0.38
FCF Yield
Median3y
-12.48
Median5y
-7.36
Competitors Valuation Multiple
The average P/S ratio for ARWR's competitors is 13.21, providing a benchmark for relative valuation. Arrowhead Pharmaceuticals Inc Corp (ARWR) exhibits a P/S ratio of 8.32, which is -36.98% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Arrowhead Pharmaceuticals Inc (ARWR) currently overvalued or undervalued?
What is Arrowhead Pharmaceuticals Inc (ARWR) fair value?
How does ARWR's valuation metrics compare to the industry average?
What is the current P/B ratio for Arrowhead Pharmaceuticals Inc (ARWR) as of Jul 19 2025?
What is the current FCF Yield for Arrowhead Pharmaceuticals Inc (ARWR) as of Jul 19 2025?
What is the current Forward P/E ratio for Arrowhead Pharmaceuticals Inc (ARWR) as of Jul 19 2025?